Cruz Fernanda F, Rocco Patricia R M
Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, and National Institute of Science and Technology for Regenerative Medicine, Rio de Janeiro, RJ, Brazil.
Stem Cell Investig. 2017 Sep 21;4:78. doi: 10.21037/sci.2017.09.02. eCollection 2017.
Four out of the ten leading causes of morbidity and mortality worldwide are lung diseases. Despite advances in comprehending the pathophysiological mechanisms involved in these disorders, for several respiratory diseases, there is still no effective treatment able to stop their natural history or reverse the morphological and functional damage they cause. In this context, recent research has supported a potential role of cell therapy for lung diseases and critical illness. The anti-inflammatory, antifibrotic, and microbicidal effects of stem cells are mainly attributed to their secretome, which contains proteins, lipids, microRNAs, and mRNAs. These are secreted in the conditioned medium and are also present in extracellular vesicles (EVs). This review will provide a detailed discussion of the role of EVs produced by mesenchymal stromal cells in preclinical experimental models of pulmonary disorders and critical illness, as well as in ongoing clinical trials.
全球十大发病和死亡原因中有四种是肺部疾病。尽管在理解这些疾病所涉及的病理生理机制方面取得了进展,但对于几种呼吸系统疾病,仍然没有有效的治疗方法能够阻止其自然病程或逆转它们所造成的形态和功能损伤。在这种背景下,最近的研究支持了细胞疗法在肺部疾病和危重症中的潜在作用。干细胞的抗炎、抗纤维化和杀菌作用主要归因于其分泌组,其中包含蛋白质、脂质、微小RNA和信使RNA。这些物质分泌在条件培养基中,也存在于细胞外囊泡(EVs)中。本综述将详细讨论间充质基质细胞产生的细胞外囊泡在肺部疾病和危重症的临床前实验模型以及正在进行的临床试验中的作用。